Semaglutide is typically administered as a subcutaneous injection (under the skin) and is taken once a week. It mimics the GLP-1 hormone in the body, which increases insulin secretion, slows gastric emptying, and helps with appetite control.
Tirzepatide is administered as a weekly subcutaneous injection (under the skin). It acts as both a GLP-1 and GIP receptor agonist, which means it increases insulin release, reduces glucagon production, slows down stomach emptying, and enhances the feeling of fullness.